iScience (Feb 2025)
Differentiation of high risk prostate cancer with a facile urinary exosome detection workflow
- Shuai Qiu,
- Yue Li,
- Zheng Zhang,
- Chunchang Li,
- Haoyu Wang,
- Ao Chen,
- Zhi Yan,
- Yang Liu,
- Zifei Li,
- Hua Huang,
- Yi Liu,
- Yiqi Seow,
- Ruibing Chen,
- Jinhong Guo,
- Simeng Wen,
- Jing Tian,
- Hongtuan Zhang,
- Ranlu Liu,
- Gang Han,
- Baolong Wang,
- Yong Wang,
- Yuanjie Niu,
- HaiFang Yin
Affiliations
- Shuai Qiu
- State Key Laboratory of Experimental Hematology & The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
- Yue Li
- State Key Laboratory of Experimental Hematology & The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
- Zheng Zhang
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China
- Chunchang Li
- Department of Urology, Tianjin Medical University General Hospital, Tianjin 300052, China
- Haoyu Wang
- Department of Urology, Tianjin Medical University General Hospital, Tianjin 300052, China
- Ao Chen
- State Key Laboratory of Experimental Hematology & The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
- Zhi Yan
- State Key Laboratory of Experimental Hematology & The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China
- Yang Liu
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China
- Zifei Li
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China
- Hua Huang
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China
- Yi Liu
- School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
- Yiqi Seow
- Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A∗STAR), Singapore 138673, Republic of Singapore; Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A∗STAR), Singapore 138673, Republic of Singapore
- Ruibing Chen
- School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China
- Jinhong Guo
- School of Sensing Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, China
- Simeng Wen
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China
- Jing Tian
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China
- Hongtuan Zhang
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China
- Ranlu Liu
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China
- Gang Han
- State Key Laboratory of Experimental Hematology & The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China; Corresponding author
- Baolong Wang
- Department of Urology, Tianjin Medical University General Hospital, Tianjin 300052, China; Corresponding author
- Yong Wang
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China; Corresponding author
- Yuanjie Niu
- Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin 300211, China; Corresponding author
- HaiFang Yin
- State Key Laboratory of Experimental Hematology & The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, School of Medical Technology & School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China; China Department of Clinical Laboratory, Tianjin Medical University General Hospital, Tianjin 300052, China; Corresponding author
- Journal volume & issue
-
Vol. 28,
no. 2
p. 111896
Abstract
Summary: Clear differentiation of high-grade and clinically insignificant prostate cancer (PCa) is critical for clinical decision-making. Here, we developed a proprietary urinary exosome isolation approach (EVLatch) and established a facile diagnostic workflow. We discovered that EEF1A1 levels, abundantly expressed on urinary exosomes, positively correlate to urinary exosome counts irrespective of source and collection time and demonstrated that EEF1A1 enables in-assay quantification of urinary exosomes. Importantly, a prostate cancer urinary EVLatch-based artificial intelligence diagnostics (PURE-AID) classification system utilizing PCA3, HOXC6, and DLX1 as targets with SPDEF for reference and EEF1A1 for quality checking, trained on 271 patients, achieved an area under the receiver operating characteristic curve (AUROC) of 0.76 in the test set of 351 patients. Combination of PURE-AID with prostate-specific antigen (PSA) and age increases AUROC to 0.80 and reduces 54.3% of unnecessary biopsies with 86.8% sensitivity. Our study provides a new classification system for differentiating high-grade PCa in a workflow- and patient-friendly manner.
